| In millions, except per share items | Mar-31-22 | Mar-31-21 | Apr-30-20 | Apr-30-19 | Apr-30-18 | Apr-30-17 | Apr-30-16 | Apr-24-15 |
| | 10-K/A | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| KOREA, REPUBLIC OF | 1.7 | | | | | | | |
| CANADA | 2.4 | 3.2 | | | | | | |
| Health and Wellness Products | 32.1 | 64.0 | 129.0 | 83.5 | 8.2 | | | |
| United States | 29.8 | 61.0 | 124.8 | 82.5 | 8.3 | | | |
| Total revenues | 34.4 | 64.8 | 131.4 | 85.9 | 8.4 | 0.0 | 0.0 | 0.0 |
| Revenue growth [+] | -46.9% | | 52.9% | 923.8% | | | | |
| CANADA | -23.9% | | | | | | | |
| Health and Wellness Products | -49.8% | | 54.6% | 920.3% | | | | |
| United States | -51.1% | | 51.3% | 892.8% | | | | |
| Other | 198.0% | | -3.0% | 1063.8% | | | | |
| Cost of goods sold | 10.8 | 18.3 | 37.9 | 28.8 | 4.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 23.6 | 46.5 | 93.5 | 57.1 | 4.4 | 0.0 | 0.0 | 0.0 |
| Gross margin | 68.6% | 71.8% | 71.2% | 66.5% | 52.3% | | | |
| Selling, general and administrative [+] | 37.0 | 48.7 | 83.8 | 58.2 | 9.6 | 0.1 | 0.0 | |
| Sales and marketing | 17.2 | 29.7 | 60.8 | 44.0 | 5.5 | 0.0 | | |
| General and administrative [+] | 19.7 | 19.0 | 23.0 | 14.3 | 4.1 | 0.0 | 0.0 | 0.0 |
| General and administrative expenses | 19.7 | 19.0 | 23.0 | 14.3 | 4.1 | | | |
| Professional fees | | | | | | 0.0 | 0.0 | |
| Research and development | | | | | 0.8 | | 0.0 | |
| Other operating expenses | | | | -0.1 | | 0.0 | 0.0 | |
| EBITDA [+] | -12.7 | -2.0 | 10.4 | -0.9 | -6.0 | -0.1 | | |
| EBITDA growth | 529.4% | | -1235.0% | -84.7% | 7871.7% | 196.5% | 1088.4% | |
| EBITDA margin | -36.8% | -3.1% | 7.9% | -1.1% | -71.6% | | | |
| Depreciation and amortization | 0.7 | 0.2 | 0.7 | 0.1 | 0.0 | 0.0 | | |
| EBIT [+] | -13.3 | -2.2 | 9.7 | -1.0 | -6.0 | -0.1 | 0.0 | 0.0 |
| EBIT growth | 512.3% | | -1069.3% | -83.4% | 7872.0% | 197.0% | 1088.4% | |
| EBIT margin | -38.7% | -3.4% | 7.4% | -1.2% | -71.7% | | | |
| Interest expense | 12.2 | 0.0 | 0.4 | 1.7 | 0.6 | 0.0 | | |
| Interest expense | 12.2 | 0.0 | 0.4 | 1.7 | 0.6 | 0.0 | | |
| Other income (expense), net [+] | 5.4 | 0.4 | -6.0 | 24.1 | -29.2 | | | |
| Gain (loss) on investments | 3.7 | | | | | | | |
| Gain (loss) on debt retirement | 1.0 | | | | | | | |
| Gain (loss) on derivative instruments | | | | 29.9 | -29.2 | | | |
| Other | -0.2 | -0.1 | | | -29.8 | | | |
| Pre-tax income | -20.1 | -1.8 | 3.3 | 21.4 | -35.8 | -0.1 | 0.0 | 0.0 |
| Income taxes | -3.0 | -0.6 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 15.1% | 32.5% | 14.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -17.1 | -1.2 | 2.8 | 21.4 | -35.8 | -0.1 | 0.0 | 0.0 |
| Net margin | -49.7% | -1.9% | 2.1% | 24.9% | -426.4% | | | |
| |
| Basic EPS [+] | ($0.08) | ($0.01) | $0.02 | $0.27 | ($0.56) | $0.00 | $0.00 | $0.00 |
| Growth | 1055.6% | | -92.0% | -147.8% | 39146.1% | 4574.9% | 2029.9% | |
| Diluted EPS [+] | ($0.08) | ($0.01) | $0.01 | $0.09 | ($0.56) | $0.00 | $0.00 | $0.00 |
| Growth | 1055.6% | | -87.0% | -116.0% | 39146.1% | 4574.9% | 2029.9% | |
| |
| Shares outstanding (basic) [+] | 206.2 | 172.0 | 131.5 | 80.5 | 64.2 | 53.4 | 836.9 | 1,500.0 |
| Growth | 19.9% | | 63.3% | 25.3% | 20.4% | -93.6% | -44.2% | |
| Shares outstanding (diluted) [+] | 206.2 | 172.0 | 239.8 | 239.8 | 64.2 | 53.4 | 836.9 | 1,500.0 |
| Growth | 19.9% | | 0.0% | 273.3% | 20.4% | -93.6% | -44.2% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |